Crossmark

When should we start renal-replacement therapy in critically ill patients with acute kidney injury: do we finally have the answer?

Published Online: 2021-05-26

Published Print: 2021-12

Authors

Bagshaw, Sean M. http://orcid.org/0000-0003-3633-6596
Hoste, Eric A.

Wald, Ron
License Information

Text and Data Mining valid from 2021-05-26

Version of Record valid from 2021-05-26
More Information

Article History

Received: 5 May 2021

Accepted: 7 May 2021

First Online: 26 May 2021

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: SMB discloses consulting fees and grant support from Baxter and consulting fees from CNA Diagnostics. EAH discloses fees for speaking from Sopachem and a travel grant from AM Pharma. RW discloses grant support and speaking fees from Baxter.

Document is current